Every material Form 8-K SCYNEXIS INC has filed with the SEC since September 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
SCYNEXIS entered a contract with the U.S. Biomedical Advanced Research and Development Authority to develop its SCY-247 antifungal candidate, with potential non-dilutive funding of up to $214 million if all options are exercised. The initial base period provides approximately $18.5 million to advance SCY-247 into a Phase 2 study in patients with invasive candidiasis. The company says its SCY-770 development plans and cash runway into 2029 are unchanged.
Contract signed September 25, 2026; base period starts September 2026 with approximately $18.5 million
Potential total funding up to $214 million; BARDA may exercise up to six options extending the term up to ten years
Cost-share arrangement; company expects to fund its share of near-term SCY-247 costs within its existing operating plan
Full contract to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026, with confidential terms redacted
SCYNEXIS said its board appointed Steven K. Burke, M.D., as a director effective September 18, 2026, and named him to the Nominating and Corporate Governance Committee. Dr. Burke has more than 30 years of biopharmaceutical experience and most recently served at Akebia Therapeutics as Senior Vice President, Chief Research and Development Officer and Chief Medical Officer. The company says his kidney disease drug development expertise supports its SCY-770 program for ADPKD.
Board appointment effective September 18, 2026; Dr. Burke serves until the 2027 Annual Meeting of Stockholders.
Non-employee director pay includes a $45,000 annual retainer and a $5,000 annual retainer for committee service.
Initial grants of options and restricted stock units each cover 5,750 shares; the option exercise price is $4.46, the September 18, 2026 closing price.
The company issued a press release on September 22, 2026, furnished as Exhibit 99.1.
SCYNEXIS said Chief Financial Officer Ivor Macleod retired effective September 9, 2026, and named Sanjay Subramanian as his successor, with an employment agreement effective the same day. Macleod will stay with the company through October 9, 2026 to support the transition. The filing contains no financial results or guidance, so the change is a leadership update rather than a measure of company performance.
Ivor Macleod ceased serving as CFO, principal financial officer and principal accounting officer effective September 9, 2026, and remains with the company through October 9, 2026.
Sanjay Subramanian's employment agreement is effective September 9, 2026, with an annual base salary of $500,000 and a discretionary annual bonus of up to 40% of base salary.
Subramanian received a stock option for 100,000 shares at $4.91, the September 9, 2026 closing price, vesting over four years.
Severance is nine months' base salary if terminated outside 12 months after a change of control, and 18 months' base salary if within that period.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SCYNEXIS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →